Key result
Staged hybrid atrial fibrillation ablation for non-paroxysmal AF resulted in 56% of patients remaining free of arrhythmia recurrence off antiarrhythmic drugs at a median 18 months follow-up.
Why the study?
The management of non-paroxysmal atrial fibrillation remains controversial.
Does a 2-stage hybrid atrial fibrillation ablation approach improve freedom from recurrent atrial arrhythmia in patients with non-paroxysmal AF?
Cohort (n=175)
Yes
Does a 2-stage hybrid atrial fibrillation ablation approach improve freedom from recurrent atrial arrhythmia in patients with non-paroxysmal AF?
The staged hybrid ablation approach for non-paroxysmal AF provides acceptable freedom from arrhythmia recurrence but carries higher complication rates, including a 2.9% risk of perioperative stroke.
Should not yet change practice given 2.9% perioperative stroke and observational design; leaves open superiority to catheter ablation.
The management of non-paroxysmal atrial fibrillation (AF) remains controversial. We examined the efficacy and safety of the 2 stage Hybrid AF ablation approach by analysing the largest series of this technique reported so far. METHODS: The approach aims to electrically isolate the left atrial posterior wall incorporating the pulmonary veins ('box-set'pattern). An initial video-assisted thoracoscopic (VATS) epicardial ablation is followed after a minimum of 8 weeks by endocardial radiofrequency catheter ablation. RESULTS: Of 175 patients from 4 European cardiothoracic centers, who underwent the surgical (COBRA Fusion, AtriCure Inc) 1st stage ablation, 166 went on to complete 2nd stage catheter ablation. At median follow up of 18 months post 2nd stage procedure 93/166 (56%) had remained free of AF or atrial tachycardia (AT) recurrence off antiarrhythmic drugs. 110/175 62.9% were in sinus rhythm off all antiarrhythmic drugs at last clinic follow-up (132/175 75.4% including those on antiarrhythmic drugs). 18 patients (10.8%) underwent a further re-do ablation (mean of 1.1 ablations per patient) 105/166 (63%) remained free of AF/AT recurrence off antiarrhythmic drugs following last ablation procedure.Latterly, ILRs have been implanted in patients (n = 56); 60% have remained fully arrhythmia free and 80% have shown AF burden < 5% at a median 14 months follow-up [IQR: 13.5 (8-21.5)]. Only 10.9% have reverted to persistent AF. 5 patients (2.9%) had a perioperative stroke and 4 patients (2.3%) exhibited persistent weakness of the right hemidiaphragm following stage 1 VATS epicardial ablation. One patient died following stroke (overall mortality 0.6%). CONCLUSIONS: In patients with non-paroxysmal AF with unfavourable characteristics for catheter ablation, the staged hybrid approach results in acceptable levels of freedom from recurrent atrial arrhythmia, however, complication rates are higher than with catheter ablation alone.
No takes yet. Share an insight, caveat, or question.
Haywood et al. (2020) conducted a cohort in non-paroxysmal atrial fibrillation (n=175). Staged hybrid atrial fibrillation ablation was evaluated on Freedom from AF or atrial tachycardia recurrence off antiarrhythmic drugs. Staged hybrid atrial fibrillation ablation for non-paroxysmal AF resulted in 56% of patients remaining free of arrhythmia recurrence off antiarrhythmic drugs at a median 18 months follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: